NEW YORK (GenomeWeb News) – Affymetrix said after the close of the market on Wednesday that its second-quarter revenues climbed 20 percent year over year as product sales increased 27 percent on the addition of the eBioscience business.

Investors reacted positively to the results, sending Affy's shares up nearly 11 percent to $4.20 in Thursday morning trade on the Nasdaq.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.